Clinical trials: Bird Flu
Influenza
H5 Adult - Chiron Study of Bird Flu Vaccine
This study is will gather critical information on the safety, tolerability, and the immunogenicity (capability of causing an immune response) of A/H5N1 (Bird flu) virus vaccine in healthy adults.
- Trial name
- NCT00280033
- Testing
- Aluminum hydroxide, Inactivated Influenza A/H5N1 Vaccine (Chiron), MF-59
- Where
- 4 sites in United States
- Volunteers
- 394 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Influenza
Inactivated Influenza A/H5N1 Vaccine in the Elderly
The purpose of this research study is to compare how the body reacts to different strengths of a new H5N1 flu vaccine. Researchers will also look at how antibodies are made after subjects receive the H5N1 flu vaccine.
- Trial name
- NCT00230750
- Testing
- Influenza A/H5N1 Vaccine
- Where
- 4 sites in United States
- Volunteers
- 261 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Influenza (Pandemic)
A/H5N1 Virus-Like Particle Antigen Dose Ranging Study With Adjuvant 2
The purpose of this study is to evaluate the immunogenicity and safety profile of the Avian flu vaccine with and without adjuvant 2 in healthy, young adults. The study is divided down into Parts A1, A2 and B.
- Trial name
- NCT01596725
- Testing
- Monovalent Avian Influenza VLP (H5N1), Monovalent Avian Influenza VLP (H5N1); Adjuvant
- Where
- 5 sites in United States
- Volunteers
- 333 people, healthy volunteers welcome
- Sponsor
- Novavax
Influenza
Phase 3 Immunogenicity and Safety Study of an Inactivated H5N1 Influenza Vaccine (Whole Virion, Vero Cell Derived)
The objectives of this study are to assess the immune response as well as the safety and tolerability of an H5N1 influenza vaccine in an adult and elderly population.
- Trial name
- NCT00462215
- Testing
- Whole virion, Vero cell-derived influenza vaccine containing H5N1 HA antigen
- Where
- 2 sites in Austria, Germany
- Volunteers
- 550 people, healthy volunteers welcome
- Sponsor
- Alachua Government Services, Inc.
Influenza
Immunogenicity and Safety Study of Inactivated Subunit H5N1 Influenza Vaccine in Prior Recipients of Live Attenuated H2N2, H6N1 and H9N2 Influenza Vaccines and in H5N1 and Live Attenuated Vaccine Naïve Individuals
The purpose of this study is to evaluate the immunogenicity and safety of inactivated subunit H5N1 influenza vaccine in individuals who have previously received live attenuated H2N2, H6N1, or H9N2 influenza vaccine, as well as in…
- Trial name
- NCT03816878
- Testing
- H5N1 pISV
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Influenza
Study of Seasonal Influenza Vaccine Against H5N1 Avian Influenza Virus
This will be a randomized, open-label, pilot feasibility study of four 2-dose vaccine regimens in healthy volunteers using two commercially available seasonal influenza vaccines to compare immune responses and in vitro…
- Trial name
- NCT01044095
- Testing
- FluMist® live, attenuated, intranasal seasonal influenza vaccine, Fluzone® inactivated influenza virus vaccine
- Where
- Thailand
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Armed Forces Research Institute of Medical Sciences, Thailand
Influenza, Influenza Vaccines
Monovalent H5N1 Vaccine GSK1557484A in Children 6 Months to < 18 Years of Age
This study will assess safety and immunogenicity of GSK Biologicals' H5N1 flu candidate vaccine GSK1557484A in children 6 months to < 18 years of age.
- Trial name
- NCT01310413
- Testing
- Influenza A (H5N1) Virus monovalent vaccine
- Where
- 17 sites in United States, Canada and 1 more
- Volunteers
- 842 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza
Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Influenza Vaccine(s) GSK3206641A and GSK3206640A Administered in Adults 18 to 64 Years of Age
The purpose of this study is to evaluate the safety and immunogenicity of different formulations of GSK Biologicals' H7N9 influenza vaccine in subjects 18 to 64 years of age.
- Trial name
- NCT01999842
- Testing
- Investigational H7N9 vaccine GSK3206641A, Investigational H7N9 vaccine GSK3206640A
- Where
- 8 sites in United States, Canada
- Volunteers
- 424 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Pandemic H5N1 Influenza
Safety and Immunogenicity of Two Doses of H5N1 Influenza Vaccine in Children
Evaluate Safety, Tolerability and Immune response of adjuvanted H5N1 cell culture derived influenza vaccine in children.
- Trial name
- NCT01776554
- Testing
- Adjuvanted H5N1 pandemic influenza vaccine
- Where
- 12 sites in United States, Thailand
- Volunteers
- 662 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Influenza
A Study to Evaluate the Safety and Immunogenicity of a Prime-boost Schedule of GSK Biologicals' Influenza Vaccine in Children
The purpose of this study is to assess the safety and immunogenicity of a prime-boost schedule of GSK Biologicals' influenza vaccine in children aged 3 to 17 years.
- Trial name
- NCT01379937
- Testing
- Influenza vaccine GSK1562902A Formulation 1, Influenza vaccine GSK1562902A Formulation 2, Havrix™
- Where
- 2 sites in Philippines
- Volunteers
- 520 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza
Study of the Safety and Immunogenicity of a Novel H5N1 Influenza Vaccine in Healthy Adults Age 18-49
The purpose of this study is to test an investigational vaccine known as "VAX161C." An "investigational" vaccine is one that is not licensed for commercial use in the by the United States (US) by the US Food and Drug…
- Trial name
- NCT01658800
- Testing
- VAX161C vaccine
- Where
- 2 sites in United States
- Volunteers
- 275 people, healthy volunteers welcome
- Sponsor
- VaxInnate Corporation
Influenza
Cell-Mediated Immune Responses to Influenza A/H5N1 Vaccine
This study may determine whether laboratory studies of people's blood cells, who have received vaccines against H5 influenza, or "bird flu," will help to decide if the vaccines are going to be prevent disease effectively.
- Trial name
- NCT00311727
- Testing
- Influenza A/H5N1
- Where
- 3 sites in United States
- Volunteers
- 339 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Influenza, Orthomyxoviridae Infections
Safety and Immunogenicity of an Intramuscular Pandemic Influenza Vaccine in Adults and the Elderly
Based on the results from a previous formulation/dosage ranging trial, this phase II multicenter, open trial was designed to determine the safety and immunogenicity of two vaccine formulation/dosages with and without adjuvant 21…
- Trial name
- NCT00415129
- Testing
- A/H5N1 inactivated, split-virion influenza virus
- Where
- 4 sites in Belgium, United Kingdom
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Influenza
Pandemic Influenza Plasmid DNA Vaccines (Needle)
The trial will enroll up to 57 subjects. Qualified normal healthy volunteers will be enrolled in the study to receive the vaccine or placebo vaccine.
- Trial name
- NCT00709800
- Testing
- VCL-IPT1, VCL-IPM1, PBS
- Where
- 3 sites in United States
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Vical
Influenza, Orthomyxoviridae Infections
Safety and Immunogenicity of 2 Formulations of an Intramuscular A/H5N1 Pandemic Influenza Vaccine in Children
This is an open, randomized, multicenter clinical trial. Objectives: To describe the safety profiles during the 21 days following each primary and booster injection.
- Conditions
- Influenza, Orthomyxoviridae Infections, Influenza A Virus Infection
- Trial name
- NCT00491985
- Testing
- A/H5N1 Inactivated, split-virion pandemic influenza vaccine, A/H5N1 Inactivated, split virion pandemic influenza vaccine
- Where
- Thailand
- Volunteers
- 240 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Phase 1 Safety Study of GelVac Nasal Powder H5N1 Influenza Vaccine
Study to Assess Safety of an Inactivated H5N1 Influenza Vaccine Administered in GelVac Nasal Powder to Healthy Young Adults
This is a double-blind, placebo controlled, safety and immunogenicity study of GelVac™ nasal powder H5N1 influenza vaccine. Healthy male and female subjects between 18 and 49 years of age who are eligible for study participation…
- Trial name
- NCT01258062
- Testing
- GelVac™ nasal powder H5N1 influenza vaccine.
- Where
- United States
- Volunteers
- 7 people, healthy volunteers welcome
- Sponsor
- Alachua Government Services, Inc.
Preventive Avian Flu
Phase I Safety and Immunogenicity of Live Attenuated Influenza H5 Candidate Vaccine Strain A/17/Turkey/Turkey/05/133 (H5N2) in Healthy Thai Volunteers
The purpose of this study is to evaluate safety and reactogenicity of live attenuated influenza H5 vaccine candidate strain A/17/turkey/Turkey/05/133 (H5N2) manufactured by GPO, in Thailand to previously healthy Thais.
- Trial name
- NCT01656356
- Testing
- Avian Flu Vaccine
- Where
- Thailand
- Volunteers
- healthy volunteers welcome
- Sponsor
- Mahidol University
Pandemic Influenza Vaccine, Prevention
Safety and Immunogenicity of Booster Dose of An Inactivated,Adjuvanted Whole-Virion Pandemic Influenza(H5N1)Vaccine
A single center, non-randomized clinical trial in two-dose primed healthy adults to evaluate the safety and immunogenicity of a booster dose of an inactivated pandemic influenza (H5N1) vaccine (whole-virion, aluminium-adjuvanted).
- Conditions
- Pandemic Influenza Vaccine, Prevention, Pandemic Influenza
- Trial name
- NCT00660257
- Testing
- pandemic influenza vaccine (H5N1 strain NIBRG-14)
- Where
- China
- Volunteers
- 57 people, healthy volunteers welcome
- Sponsor
- Sinovac Biotech Co., Ltd
Avian Influenza, Bird Flu
Safety Study of an Oral Vaccine to Prevent Avian Influenza
The purpose of this study is to demonstrate the safety and immunogenicity of an oral vaccine to prevent avian influenza. Volunteers will receive either one or two doses of research vaccine or placebo as part of this study.
- Trial name
- H5N1 (NCT01335347)
- Testing
- ND1.1
- Where
- United States
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- Vaxart
Influenza
Safety and Immunogenicity of Vaccine in Adults at Occupational Risk for Influenza A (H5N1) Exposure
The purpose of this study is to characterize the immunogenicity and safety of 3 doses of GSK's avian flu vaccine GSK 1557484A given at different time intervals to adults aged 18 years or greater who are at increased occupational…
- Trial name
- NCT01045564
- Testing
- GSK influenza virus H5N1 vaccine 1557484A
- Where
- 3 sites in United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- GlaxoSmithKline